Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now accepted as the best therapeutic option for patients with T2DM and cardiovascular disease, heart failure and/or chronic kidney disease. The gene discussed is GLP1R; the disease is heart failure.